Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Operating expenses
Research and development	$ 9,824,000	$ 8,372,000
Acquired in-process research and development		6,767,000
General and administrative	9,265,000	2,519,000
Loss on sale of assets (Note 6)	663,000
Total operating expenses	19,752,000	17,658,000
Loss from operations	(19,752,000)	(17,658,000)
Other income (expense)
Interest income	96,000	245,000
Interest expense	(931,000)	(1,013,000)
Other income (expense)	(9,000)
Change in fair value of derivative liabilities	1,117,000	1,724,000
Total other income (expense), net	273,000	956,000
Loss before income taxes	(19,479,000)	(16,702,000)
Net loss	(19,479,000)	(16,702,000)
Unrealized gain on investments		7,000
Comprehensive loss	$ (19,479,000)	$ (16,695,000)
Per share information:
Net loss per share, basic	$ (2.49)	$ (3.59)
Weighted average shares outstanding, basic	7,827,197	4,652,777
Net loss per share, diluted	$ (2.55)	$ (3.59)
Weighted average shares outstanding, diluted	8,009,909	4,652,777